GABRA3

VALUE_ERROR (nil)

Identifiers
Aliases|
External IDs| GeneCards: [1]
Orthologs
Species| Human| Mouse
Entrez| |

n/a

n/a

Ensembl| |

n/a

n/a

UniProt| |

n/a

n/a

RefSeq (mRNA)| |

n/a

n/a

RefSeq (protein)| |

n/a

n/a

Location (UCSC)| n/a| n/a
PubMed search| n/a| n/a
Wikidata
| View/Edit Human|

|

Gamma-aminobutyric acid receptor subunit alpha-3 is a protein that in humans is encoded by the GABRA3 gene.[1]

## Contents

* 1 Function
* 2 Subunit selective ligands
* 2.1 Agonists
* 2.2 Inverse agonists
* 3 RNA editing
* 3.1 Type
* 3.2 Location
* 3.3 Regulation
* 3.4 Conservation
* 3.5 Consequences
* 3.5.1 Structure
* 3.5.2 Function
* 4 See also
* 5 References
* 6 Further reading
* 7 External links

## Function

[edit | edit source]

GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABAA receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABAA receptor. At least 16 distinct subunits of GABA-A receptors have been identified.[1] GABA receptors are composed of 5 subunits with an extracellular ligand binding domains and ion channel domains that are integral to the membrane.Ligand binding to these receptors activates the channel.[2]

## Subunit selective ligands

[edit | edit source]

Recent research has produced several ligands that are selective for GABAA receptors containing the α3 subunit. Subtype-selective agonists for α3 produce anxiolytic effects without sedative, amnesia, ataxia. [3] selective a3 agonists also show lack of dependence, [4] and could make them superior to currently marketed drugs.

### Agonists

[edit | edit source]

* Adipiplon
* PWZ-029 (partial agonist at α3, partial inverse agonist at α5)
* TP003 (Selective full agonist at α3)

### Inverse agonists

[edit | edit source]

* α3IA

## RNA editing

[edit | edit source]

Editing element of GABA-3 exon 9

File:GABRA3RNA.png

Conserved secondary structure and sequence conservation of GABA3

Identifiers
Symbol| GABA3
Rfam| RF01803
Other data
RNA type| Cis-reg;
Domain(s)| Eukaryota;
SO| 0005836
PDB structures| PDBe

The GABRA3 transcript undergoes pre-mRNA editing by the ADAR family of enzymes.[5] A-to-I editing changes an isoleucine codon to code for a methionine residue. This editing is thought to be important for brain development, as the level of editing is low at birth and becomes almost 100% in an adult brain.[5]

The editing occurs in an RNA stem-loop found in exon 9.[5] The structured loci was identified using a specialised bioinformatics screen[6] of the human genome. The proposed function of the edit is to alter chloride permeability of the GABA receptor.[5]

At the time of discovery, Kv1.1 mRNA was the only previously known mammalian coding site containing both the edit sequence and the editing complementary sequence.[7]

### Type

[edit | edit source]

A to I RNA editing is catalyzed by a family of adenosine deaminases acting on RNA (ADARs) that specifically recognize adenosines within double-stranded regions of pre-mRNAs and deaminate them to inosine. Inosines are recognised as guanosine by the cells translational machinery. There are three members of the ADAR family ADARs 1-3, with ADAR1 and ADAR2 being the only enzymatically active members. ADAR3 is thought to have a regulatory role in the brain. ADAR1 and ADAR 2 are widely expressed in tissues, while ADAR3 is restricted to the brain. The double-stranded regions of RNA are formed by base-pairing between residues in the close to region of the editing site, with residues usually in a neighboring intron but can be an exonic sequence. The region that base pairs with the editing region is known as an Editing Complementary Sequence (ECS).

### Location

[edit | edit source]

The editing site was previously believed to be a single nucleotide polymorphism.[8] The editing site is found at amino acid 5 of transmembrane domain 3 of exon 9. The predicted double-stranded RNA structure is interrupted by three bulges and a mismatch at the editing site. The double-stranded region is 22 base pairs in length. As with editing of the KCNA1 gene product,[7] the editing region and the editing complementary sequence are both found in exonic regions. In the pre=mRNA of GABRA3, both are found within exon 9.[5] The other subunits of the receptor are thought not to be edited, as their predicted secondary structure is less likely to be edited. Also, alpha subunits 1 and 6 have a uridine instead of an adenosine at the site corresponding to the editing site in alpha subunit 3.[5] Point mutation experiments determined that a Cytidine 15 nucleotides from the editing site is the base opposite the edited base.[5] Using a GABRA3 mini-gene that encodes for exon 9 cotransfected to HEK293 cells with either ADAR1 or -2 or none, it was determined that both active ADARs can efficiently edited the site in exon 9.[5]

### Regulation

[edit | edit source]

The mRNA expression of the alpha 3 subunit is developmentally regulated. It is the dominant subunit in the forebrain tissue at birth, gradually decreasing in prominence as alpha subunit 1 takes over. Also experiments with mice have demonstrated that editing of pre-mRNA alpha 3 subunit increases from 50% at birth to nearly 100% in adult.[5] Editing levels are lower in the hippocampus[9]

### Conservation

[edit | edit source]

At the location corresponding to the I/M site of GABRA3 in frog and pufferfish there is a genomically encoded methionine. In all other species, there is an isoleucine at the position.[10]

### Consequences

[edit | edit source]

#### Structure

[edit | edit source]

Editing results in a codon change from (AUA)I to (AUG)M at the editing site. This results in translation of a methionine instead of an isoleucine at the I/M site. The amino acid change occurs in the transmembrane domain 3. The 4 transmembrane domains of each of the 5 subunits that make up the receptor interact to form the receptor channel. It is likely that the change of amino acids disturbs the structure, effecting gating and inactivation of the channel.[11] This is because methionine has a larger side chain.[5]

#### Function

[edit | edit source]

While the effect of editing on protein function is unknown, the developmental increase in editing does correspond to changes in function of the GAGAA receptor. GABA binding leads to chloride channel activation, resulting in rapid increase in concentration of the ion. Initially, the receptor is an excitatory receptor, mediating depolarisation (efflux of Cl− ions) in immature neurons before changing to an inhibitory receptor, mediating hyperpolarisation(influx of Cl− ions) later on.[12] GABAA converts to an inhibitory receptor from an excitatory receptor by the upregulation of KCC2 cotransporter. This decreases the concentration of Cl− ion within cells. Therefore, the GAGAA subunits are involved in determining the nature of the receptor in response to GABA ligand.[13] These changes suggest that editing of the subunit is important in the developing brain by regulating the Cl− permeability of the channel during development. The unedited receptor is activated faster and deactivates slower than the edited receptor.[5]

## See also

[edit | edit source]

* GABAA receptor

## References

[edit | edit source]

1. ↑ 1.0 1.1 "Entrez Gene: GABRA3 gamma-aminobutyric acid (GABA) A receptor, alpha 3".
2. ↑ Cromer BA, Morton CJ, Parker MW (June 2002). "Anxiety over GABA(A) receptor structure relieved by AChBP". Trends in Biochemical Sciences. 27 (6): 280–7. doi:10.1016/S0968-0004(02)02092-3. PMID 12069787.
3. ↑ Fischer BD, Atack JR, Platt DM, et al. (2011). "Contribution of GABAA receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys". Psychopharmacology. 215 (2): 311–319. doi:10.1007/s00213-010-2142-y. PMC 3097109. PMID 21190016.
4. ↑ Cheng T, Wallace D, Ponteri B, et al. (2018). "Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects". Neuropsychiatr. Dis. Treat. 14: 1351–1361. doi:10.2147/NDT.S164307. PMC 5973310. PMID 29872302.
5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 Ohlson J, Pedersen JS, Haussler D, Ohman M (May 2007). "Editing modifies the GABA(A) receptor subunit alpha3". RNA. 13 (5): 698–703. doi:10.1261/rna.349107. PMC 1852825. PMID 17369310.
6. ↑ Ohlson J, Ensterö M, Sjöberg BM, Ohman M (October 2005). "A method to find tissue-specific novel sites of selective adenosine deamination". Nucleic Acids Research. 33 (19): e167. doi:10.1093/nar/gni169. PMC 1275595. PMID 16257978.
7. ↑ 7.0 7.1 Bhalla T, Rosenthal JJ, Holmgren M, Reenan R (October 2004). "Control of human potassium channel inactivation by editing of a small mRNA hairpin". Nature Structural & Molecular Biology. 11 (10): 950–6. doi:10.1038/nsmb825. PMID 15361858.
8. ↑ Wang Q, Miyakoda M, Yang W, Khillan J, Stachura DL, Weiss MJ, Nishikura K (February 2004). "Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene". The Journal of Biological Chemistry. 279 (6): 4952–61. doi:10.1074/jbc.M310162200. PMID 14613934.
9. ↑ Rula EY, Lagrange AH, Jacobs MM, Hu N, Macdonald RL, Emeson RB (June 2008). "Developmental modulation of GABA(A) receptor function by RNA editing". The Journal of Neuroscience. 28 (24): 6196–201. doi:10.1523/JNEUROSCI.0443-08.2008. PMC 2746000. PMID 18550761.
10. ↑ Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, Diekhans M, Furey TS, Harte RA, Hsu F, Hillman-Jackson J, Kuhn RM, Pedersen JS, Pohl A, Raney BJ, Rosenbloom KR, Siepel A, Smith KE, Sugnet CW, Sultan-Qurraie A, Thomas DJ, Trumbower H, Weber RJ, Weirauch M, Zweig AS, Haussler D, Kent WJ (January 2006). "The UCSC Genome Browser Database: update 2006". Nucleic Acids Research. 34 (Database issue): D590–8. doi:10.1093/nar/gkj144. PMC 1347506. PMID 16381938.
11. ↑ Fisher JL (April 2004). "A mutation in the GABAA receptor alpha 1 subunit linked to human epilepsy affects channel gating properties". Neuropharmacology. 46 (5): 629–37. doi:10.1016/j.neuropharm.2003.11.015. PMID 14996540.
12. ↑ Ben-Ari Y (September 2002). "Excitatory actions of gaba during development: the nature of the nurture". Nature Reviews. Neuroscience. 3 (9): 728–39. doi:10.1038/nrn920. PMID 12209121.
13. ↑ Böhme I, Rabe H, Lüddens H (August 2004). "Four amino acids in the alpha subunits determine the gamma-aminobutyric acid sensitivities of GABAA receptor subtypes". The Journal of Biological Chemistry. 279 (34): 35193–200. doi:10.1074/jbc.M405653200. PMID 15199051.

## Further reading

[edit | edit source]

* Buckle VJ, Fujita N, Ryder-Cook AS, Derry JM, Barnard PJ, Lebo RV, Schofield PR, Seeburg PH, Bateson AN, Darlison MG (November 1989). "Chromosomal localization of GABAA receptor subunit genes: relationship to human genetic disease". Neuron. 3 (5): 647–54. doi:10.1016/0896-6273(89)90275-4. PMID 2561974.
* Bell MV, Bloomfield J, McKinley M, Patterson MN, Darlison MG, Barnard EA, Davies KE (December 1989). "Physical linkage of a GABAA receptor subunit gene to the DXS374 locus in human Xq28". American Journal of Human Genetics. 45 (6): 883–8. PMC 1683479. PMID 2574000.
* Tögel M, Mossier B, Fuchs K, Sieghart W (April 1994). "gamma-Aminobutyric acidA receptors displaying association of gamma 3-subunits with beta 2/3 and different alpha-subunits exhibit unique pharmacological properties". The Journal of Biological Chemistry. 269 (17): 12993–8. PMID 8175718.
* Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CI, Whiting PJ (June 1993). "Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors". Molecular Pharmacology. 43 (6): 970–5. PMID 8391122.
* Belelli D, Lambert JJ, Peters JA, Wafford K, Whiting PJ (September 1997). "The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid". Proceedings of the National Academy of Sciences of the United States of America. 94 (20): 11031–6. doi:10.1073/pnas.94.20.11031. PMC 23576. PMID 9380754.
* Huang RQ, Dillon GH (July 1998). "Maintenance of recombinant type A gamma-aminobutyric acid receptor function: role of protein tyrosine phosphorylation and calcineurin". The Journal of Pharmacology and Experimental Therapeutics. 286 (1): 243–55. PMID 9655866.
* Amir R, Dahle EJ, Toriolo D, Zoghbi HY (January 2000). "Candidate gene analysis in Rett syndrome and the identification of 21 SNPs in Xq". American Journal of Medical Genetics. 90 (1): 69–71. doi:10.1002/(SICI)1096-8628(20000103)90:1<69::AID-AJMG12>3.0.CO;2-W. PMID 10602120.
* Bedford FK, Kittler JT, Muller E, Thomas P, Uren JM, Merlo D, Wisden W, Triller A, Smart TG, Moss SJ (September 2001). "GABA(A) receptor cell surface number and subunit stability are regulated by the ubiquitin-like protein Plic-1". Nature Neuroscience. 4 (9): 908–16. doi:10.1038/nn0901-908. PMID 11528422.
* Chou KC (April 2004). "Modelling extracellular domains of GABA-A receptors: subtypes 1, 2, 3, and 5". Biochemical and Biophysical Research Communications. 316 (3): 636–42. doi:10.1016/j.bbrc.2004.02.098. PMID 15033447.
* Henkel V, Baghai TC, Eser D, Zill P, Mergl R, Zwanzger P, Schüle C, Bottlender R, Jäger M, Rupprecht R, Hegerl U, Möller HJ, Bondy B (April 2004). "The gamma amino butyric acid (GABA) receptor alpha-3 subunit gene polymorphism in unipolar depressive disorder: a genetic association study". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 126B (1): 82–7. doi:10.1002/ajmg.b.20137. PMID 15048654.
* Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, Yamamoto J, Sekine M, Tsuritani K, Wakaguri H, Ishii S, Sugiyama T, Saito K, Isono Y, Irie R, Kushida N, Yoneyama T, Otsuka R, Kanda K, Yokoi T, Kondo H, Wagatsuma M, Murakawa K, Ishida S, Ishibashi T, Takahashi-Fujii A, Tanase T, Nagai K, Kikuchi H, Nakai K, Isogai T, Sugano S (January 2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes". Genome Research. 16 (1): 55–65. doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560.
* Pedersen JS, Bejerano G, Siepel A, Rosenbloom K, Lindblad-Toh K, Lander ES, Kent J, Miller W, Haussler D (April 2006). "Identification and classification of conserved RNA secondary structures in the human genome". PLoS Computational Biology. 2 (4): e33. doi:10.1371/journal.pcbi.0020033. PMC 1440920. PMID 16628248.

## External links

[edit | edit source]

* GABRA3+protein,+human at the US National Library of Medicine Medical Subject Headings (MeSH)
* [2]
*   * Page for Editing element of GABA-3 exon 9 at Rfam

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

* v
* t
* e

Ion channel, cell surface receptor: ligand-gated ion channels

Cys-loop receptors|

| 5-HT/serotonin|

* 5-HT3
* A
* B
* C
* D
* E

|

GABA|

* GABAA
* α1
* α2
* α3
* α4
* α5
* α6
* β1
* β2
* β3
* γ1
* γ2
* γ3
* δ
* ε
* π
* θ
* GABAA-ρ
* ρ1
* ρ2
* ρ3

Glycine|

* α1
* α2
* α3
* α4
* β

Nicotinic acetylcholine|

* monomers: α1
* α2
* α3
* α4
* α5
* α6
* α7
* α9
* α10
* β1
* β2
* β3
* β4
* δ
* ε

* pentamers: (α3)2(β4)3
* (α4)2(β2)3
* (α7)5
* (α1)2(β4)3 \- Ganglion type
* (α1)2β1δε - Muscle type

Zinc|

* Zinc-activated

Ionotropic glutamates|

| Ligand-gated only|

* AMPA (1
* 2
* 3
* 4)
* Kainate
* 1
* 2
* 3
* 4
* 5

|

Voltage- and ligand-gated|

* NMDA
* 1
* 2A
* 2B
* 2C
* 2D
* 3A
* 3B
* L1A
* L1B

‘Orphan’|

* GluD
* δ1
* δ2

ATP-gated channels|

| Purinergic receptors|

* P2X
* 1
* 2
* 3
* 4
* 5
* 6
* 7

|

* v
* t
* e

GABA receptor modulators

Ionotropic|

| GABAA|

* Agonists: (+)-Catechin
* Bamaluzole
* Barbiturates (e.g., phenobarbital)
* BL-1020
* DAVA
* Dihydromuscimol
* GABA
* Gabamide
* GABOB
* Gaboxadol (THIP)
* Homotaurine (tramiprosate, 3-APS)
* Ibotenic acid
* iso-THAZ
* iso-THIP
* Isoguvacine
* Isomuscimol
* Isonipecotic acid
* Kojic amine
* Lignans (e.g., honokiol)
* Methylglyoxal
* Monastrol
* Muscimol
* Nefiracetam
* Neuroactive steroids (e.g., allopregnanolone)
* Org 20599
* PF-6372865
* Phenibut
* Picamilon
* P4S
* Progabide
* Propofol
* Quisqualamine
* SL-75102
* TACA
* TAMP
* Terpenoids (e.g., borneol)
* Thiomuscimol
* Tolgabide
* ZAPA

* Positive modulators (abridged; see here for a full list): α-EMTBL
* Alcohols (e.g., ethanol)
* Anabolic steroids
* Avermectins (e.g., ivermectin)
* Barbiturates (e.g., phenobarbital)
* Benzodiazepines (e.g., diazepam)
* Bromide compounds (e.g., potassium bromide)
* Carbamates (e.g., meprobamate)
* Carbamazepine
* Chloralose
* Chlormezanone
* Clomethiazole
* Dihydroergolines (e.g., ergoloid (dihydroergotoxine))
* Etazepine
* Etifoxine
* Fenamates (e.g., mefenamic acid)
* Flavonoids (e.g., apigenin, hispidulin)
* Fluoxetine
* Flupirtine
* Imidazoles (e.g., etomidate)
* Kava constituents (e.g., kavain)
* Lanthanum
* Loreclezole
* Monastrol
* Neuroactive steroids (e.g., allopregnanolone, cholesterol, THDOC)
* Niacin
* Nicotinamide (niacinamide)
* Nonbenzodiazepines (e.g., β-carbolines (e.g., abecarnil), cyclopyrrolones (e.g., zopiclone), imidazopyridines (e.g., zolpidem), pyrazolopyrimidines (e.g., zaleplon))
* Norfluoxetine
* Petrichloral
* Phenols (e.g., propofol)
* Phenytoin
* Piperidinediones (e.g., glutethimide)
* Propanidid
* Pyrazolopyridines (e.g., etazolate)
* Quinazolinones (e.g., methaqualone)
* Retigabine (ezogabine)
* ROD-188
* Skullcap constituents (e.g., baicalin)
* Stiripentol
* Sulfonylalkanes (e.g., sulfonmethane (sulfonal))
* Topiramate
* Valerian constituents (e.g., valerenic acid)
* Volatiles/gases (e.g., chloral hydrate, chloroform, diethyl ether, paraldehyde, sevoflurane)

* Antagonists: Bicuculline
* Coriamyrtin
* Dihydrosecurinine
* Gabazine (SR-95531)
* Hydrastine
* Hyenachin (mellitoxin)
* PHP-501
* Pitrazepin
* Securinine
* Sinomenine
* SR-42641
* SR-95103
* Thiocolchicoside
* Tutin

* Negative modulators: 1,3M1B
* 3M2B
* 11-Ketoprogesterone
* 17-Phenylandrostenol
* α5IA (LS-193,268)
* β-CCB
* β-CCE
* β-CCM
* β-CCP
* β-EMGBL
* Anabolic steroids
* Amiloride
* Anisatin
* β-Lactams (e.g., penicillins, cephalosporins, carbapenems)
* Basmisanil
* Bemegride
* Bicyclic phosphates (TBPS, TBPO, IPTBO)
* BIDN
* Bilobalide
* Bupropion
* CHEB
* Chlorophenylsilatrane
* Cicutoxin
* Cloflubicyne
* Cyclothiazide
* DHEA
* DHEA-S
* Dieldrin
* (+)-DMBB
* DMCM
* DMPC
* EBOB
* Etbicyphat
* FG-7142 (ZK-31906)
* Fiproles (e.g., fipronil)
* Flavonoids (e.g., amentoflavone, oroxylin A)
* Flumazenil
* Fluoroquinolones (e.g., ciprofloxacin)
* Flurothyl
* Furosemide
* Iomazenil (123I)
* IPTBO
* Isopregnanolone (sepranolone)
* L-655,708
* Laudanosine
* Leptazol
* Lindane
* MaxiPost
* Morphine
* Morphine-3-glucuronide
* MRK-016
* Naloxone
* Naltrexone
* Nicardipine
* Nonsteroidal antiandrogens (e.g., apalutamide, bicalutamide, enzalutamide, flutamide, nilutamide)
* Oenanthotoxin
* Pentylenetetrazol (pentetrazol)
* Phenylsilatrane
* Picrotoxin (i.e., picrotin, picrotoxinin and dihydropicrotoxinin)
* Pregnenolone sulfate
* Propybicyphat
* PWZ-029
* Radequinil
* Ro 15-4513
* Ro 19-4603
* RO4882224
* RO4938581
* Sarmazenil
* SCS
* Suritozole
* TB-21007
* TBOB
* TBPS
* TCS-1105
* Terbequinil
* TETS
* Thujone
* U-93631
* Zinc
* ZK-93426

|

GABAA-ρ|

* Agonists: BL-1020
* CACA
* CAMP
* Homohypotaurine
* GABA
* GABOB
* Ibotenic acid
* Isoguvacine
* Muscimol
* N4-Chloroacetylcytosine arabinoside
* Picamilon
* Progabide
* TACA
* TAMP
* Thiomuscimol
* Tolgabide

* Positive modulators: Allopregnanolone
* Alphaxolone
* ATHDOC
* Lanthanides

* Antagonists: (S)-2-MeGABA
* (S)-4-ACPBPA
* (S)-4-ACPCA
* 2-MeTACA
* 3-APMPA
* 4-ACPAM
* 4-GBA
* cis-3-ACPBPA
* CGP-36742 (SGS-742)
* DAVA
* Gabazine (SR-95531)
* Gaboxadol (THIP)
* I4AA
* Isonipecotic acid
* Loreclezole
* P4MPA
* P4S
* SKF-97541
* SR-95318
* SR-95813
* TPMPA
* trans-3-ACPBPA
* ZAPA

* Negative modulators: 5α-Dihydroprogesterone
* Bilobalide
* Loreclezole
* Picrotoxin (picrotin, picrotoxinin)
* Pregnanolone
* ROD-188
* THDOC
* Zinc

Metabotropic|

| GABAB|

* Agonists: 1,4-Butanediol
* 4-Fluorophenibut
* Aceburic acid
* Arbaclofen
* Arbaclofen placarbil
* Baclofen
* BL-1020
* GABA
* Gabamide
* GABOB
* GBL
* GHB
* GHBAL
* GHV
* GVL
* Isovaline
* Lesogaberan
* Phenibut
* Picamilon
* Progabide
* Sodium oxybate
* SKF-97,541
* SL 75102
* Tolgabide
* Tolibut

* Positive modulators: ADX-71441
* BHF-177
* BHFF
* BSPP
* CGP-7930
* CGP-13501
* GS-39783
* rac-BHFF
* KK-92A

* Antagonists: 2-Hydroxysaclofen
* CGP-35348
* CGP-46381
* CGP-52432
* CGP-54626
* CGP-55845
* CGP-64213
* DAVA
* Homotaurine (tramiprosate, 3-APS)
* Phaclofen
* Saclofen
* SCH-50911
* SKF-97541

* Negative modulators: Compound 14

|

See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template
*[GABA]: γ-Aminobutyric acid
*[GABAA]: γ-Aminobutyric acid A receptor
*[GABAA-ρ]: γ-Aminobutyric acid A-rho receptor
*[GABAB]: γ-Aminobutyric acid B receptor